Biogen (BIIB) Gets a Hold from Citi
I'm PortAI, I can summarize articles.
According to TipRanks, Meacham is a 4-star analyst with an average return of 4.2% and a 55.14% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals. In addition to Citi, Biogen also received a Hold from Morgan Stanley’s Terence Flynn in a report issued on October 10. However, on October 8, RBC Capital maintained a Buy rating on Biogen (NASDAQ: BIIB).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments